Clinical TrialsOsivax OVX836 Misses Phase 2b Influenza Vaccine Target Osivax OVX836 Misses Phase 2b Influenza Vaccine Target Read Post »
Clinical TrialsGalderma Reports Positive Itch Response for Nemolizumab in Young Children Galderma Reports Positive Itch Response for Nemolizumab in Young Children Read Post »
Clinical TrialsEC-104 Shows Durable Improvement in Phase 2 DME Trial EC-104 Shows Durable Improvement in Phase 2 DME Trial Read Post »
Clinical TrialsLilly’s Omvoh Achieves Deeper Remission in IBD Lilly’s Omvoh Achieves Deeper Remission in IBD Read Post »
Clinical TrialsinvIOs’ APN401 Shows Early Safety Findings and Disease Stabilization in A... invIOs’ APN401 Shows Early Safety Findings and Disease Stabilization in A... Read Post »
Clinical TrialsCellectar’s Iopofosine I 131 Shows 87.5% Response Rate in WM Cellectar’s Iopofosine I 131 Shows 87.5% Response Rate in WM Read Post »
New Drug ApprovalFDA Expands ANKTIVA Approval to High-Grade Papillary-Only Bladder Cancer FDA Expands ANKTIVA Approval to High-Grade Papillary-Only Bladder Cancer Read Post »
Clinical TrialsZenas Obexelimab Show Sustained Flare Control, Reduced Steroid Toxicity in ... Zenas Obexelimab Show Sustained Flare Control, Reduced Steroid Toxicity in ... Read Post »
Clinical TrialsVanda VQW-765 Phase 3 Trial Fails in Social Anxiety Vanda VQW-765 Phase 3 Trial Fails in Social Anxiety Read Post »
Clinical TrialsArrowhead ARO-MAPT Cuts CSF Tau by 73% in Phase 1/2a Arrowhead ARO-MAPT Cuts CSF Tau by 73% in Phase 1/2a Read Post »
Clinical TrialsSitryx Reports Early Improvements in Atopic Dermatitis With SYX-5219 Sitryx Reports Early Improvements in Atopic Dermatitis With SYX-5219 Read Post »
Clinical TrialsTAK-881 Meets Primary PK Endpoint, Reducing Infusion Burden in PID TAK-881 Meets Primary PK Endpoint, Reducing Infusion Burden in PID Read Post »
Clinical TrialsEntrada Reports Early Dystrophin Increase with ENTR-601-45 in DMD Entrada Reports Early Dystrophin Increase with ENTR-601-45 in DMD Read Post »
Clinical TrialsVerastem’s VS-7375 Shows 50% Response Rate in Pancreatic Cancer Verastem’s VS-7375 Shows 50% Response Rate in Pancreatic Cancer Read Post »
Clinical TrialsSKYRIZI Achieves 35.8% Remission in AFFIRM Crohn’s Trial SKYRIZI Achieves 35.8% Remission in AFFIRM Crohn’s Trial Read Post »
Clinical TrialsBiomea’s Oral GLP-1 Candidate BMF-650 Shows Early Weight Loss Biomea’s Oral GLP-1 Candidate BMF-650 Shows Early Weight Loss Read Post »
Clinical TrialsBeam Reports Improved Fasting Tolerance With BEAM-301 Base Editing in GSDIa Beam Reports Improved Fasting Tolerance With BEAM-301 Base Editing in GSDIa Read Post »
Clinical Trialsāshibio Reports 86.2% Lower FOP Flare-Up, Advances Vantictumab for ADO2 āshibio Reports 86.2% Lower FOP Flare-Up, Advances Vantictumab for ADO2 Read Post »
Clinical TrialsTREMFYA Shows Fistula Remission in Crohn’s Disease TREMFYA Shows Fistula Remission in Crohn’s Disease Read Post »
Clinical TrialsSyndax Ends Axatilimab Development in IPF After Phase 2 Failure Syndax Ends Axatilimab Development in IPF After Phase 2 Failure Read Post »
Clinical TrialsBioNTech BNT113 Misses PFS Endpoint in HPV16+ HNSCC Trial BioNTech BNT113 Misses PFS Endpoint in HPV16+ HNSCC Trial Read Post »
Clinical TrialsTortugas Reports Positive Phase 2b Results for Obuprazine in Schizophrenia Tortugas Reports Positive Phase 2b Results for Obuprazine in Schizophrenia Read Post »
Clinical TrialsMirum’s LIVMARLI Cuts Bile Acids by 70%, Improves Itching in Phase 3 Tria... Mirum’s LIVMARLI Cuts Bile Acids by 70%, Improves Itching in Phase 3 Tria... Read Post »
Clinical TrialsAstraZeneca’s Efzimfotase Alfa Misses Endpoint in Hypophosphatasia Tr... AstraZeneca’s Efzimfotase Alfa Misses Endpoint in Hypophosphatasia Tr... Read Post »
Clinical TrialsANI Reports Long-Term Uveitis Results Alongside IOP-Related Safety Findings ANI Reports Long-Term Uveitis Results Alongside IOP-Related Safety Findings Read Post »
Clinical TrialsBMS Reports Admilparant 60 mg Meets Endpoint in IPF Trial, 120 mg Falls Sho... BMS Reports Admilparant 60 mg Meets Endpoint in IPF Trial, 120 mg Falls Sho... Read Post »
Clinical TrialsAbbVie Presents SKYRIZI Remission Results and RINVOQ Real-World Outcomes AbbVie Presents SKYRIZI Remission Results and RINVOQ Real-World Outcomes Read Post »
Clinical TrialsAcoramidis Shows 34% Lower Hazard of Composite Clinical Worsening Than Tafa... Acoramidis Shows 34% Lower Hazard of Composite Clinical Worsening Than Tafa... Read Post »
Clinical TrialsClinical Remission Reaches 71.4% With Subcutaneous Infliximab in Matched Cr... Clinical Remission Reaches 71.4% With Subcutaneous Infliximab in Matched Cr... Read Post »
Clinical TrialsRoche Reports Sustained Vision and Anatomical Improvements with Vamikibart ... Roche Reports Sustained Vision and Anatomical Improvements with Vamikibart ... Read Post »
Clinical TrialsBridgeBio’s Encaleret Shows PTH Recovery and Symptom Improvements in ... BridgeBio’s Encaleret Shows PTH Recovery and Symptom Improvements in ... Read Post »
Clinical TrialsCardurion’s Tovinontrine Phase 2 Results Show Greater NT-proBNP Reduc... Cardurion’s Tovinontrine Phase 2 Results Show Greater NT-proBNP Reduc... Read Post »
Clinical TrialsVertex Reports Promising Pancreatic Function Gains With ALYFTREK in Young C... Vertex Reports Promising Pancreatic Function Gains With ALYFTREK in Young C... Read Post »
Clinical TrialsSling’s Linsitinib Maintains Proptosis Response Through Week 72 in LI... Sling’s Linsitinib Maintains Proptosis Response Through Week 72 in LI... Read Post »
New Drug ApprovalFDA Approves HOVILPRI for Refractory HSV Lesions in Immunocompromised Adult... FDA Approves HOVILPRI for Refractory HSV Lesions in Immunocompromised Adult... Read Post »
Clinical TrialsICOTYDE Sustains PASI 90 Response Through Two Years ICOTYDE Sustains PASI 90 Response Through Two Years Read Post »
Clinical TrialsLilly’s Taltz–Zepbound Study Links Neutrophils to Psoriasis Response Lilly’s Taltz–Zepbound Study Links Neutrophils to Psoriasis Response Read Post »
Clinical TrialscAMPfield’s Prifemilast Shows 29.3-Point PASI 75 Advantage Over Aprem... cAMPfield’s Prifemilast Shows 29.3-Point PASI 75 Advantage Over Aprem... Read Post »
New Drug ApprovalFDA Approves Tecentriq Plus Chemotherapy for Stage III dMMR Colon Cancer FDA Approves Tecentriq Plus Chemotherapy for Stage III dMMR Colon Cancer Read Post »
New Drug ApprovalTeva Wins FDA Approval for WELTRUZA in Schizophrenia Teva Wins FDA Approval for WELTRUZA in Schizophrenia Read Post »
Clinical TrialsAlumis Reports Highest PASI 100 Response With Envudeucitinib Among Oral Pso... Alumis Reports Highest PASI 100 Response With Envudeucitinib Among Oral Pso... Read Post »
Clinical TrialsBMS Reports 51% Lower Progression Risk With ZENBEXUS BMS Reports 51% Lower Progression Risk With ZENBEXUS Read Post »
Clinical TrialsInnovent Reports TEPEZZA-Consistent Proptosis Reduction With SYCUME in Inac... Innovent Reports TEPEZZA-Consistent Proptosis Reduction With SYCUME in Inac... Read Post »
Clinical TrialsPharvaris Reports Positive Results for Oral Deucrictibant in HAE Trial Pharvaris Reports Positive Results for Oral Deucrictibant in HAE Trial Read Post »
Clinical TrialsEndeavor’s Taladegib Improves Lung Function in Phase 2b IPF Trial Endeavor’s Taladegib Improves Lung Function in Phase 2b IPF Trial Read Post »
Clinical TrialsTopical Sildenafil Shows 187-Fold Lower Systemic Peak Than Oral Dose in Dar... Topical Sildenafil Shows 187-Fold Lower Systemic Peak Than Oral Dose in Dar... Read Post »
Clinical TrialsCandel Reports 24.5-Month Median Overall Survival with Aglatimagene Besaden... Candel Reports 24.5-Month Median Overall Survival with Aglatimagene Besaden... Read Post »
Clinical TrialsForte-Acquired FB102 Delivers Positive Phase 2 Results in Celiac Disease Forte-Acquired FB102 Delivers Positive Phase 2 Results in Celiac Disease Read Post »
Clinical Trialsargenx Halts Phase 3 UNITY Study of Efgartigimod After Futility Review in S... argenx Halts Phase 3 UNITY Study of Efgartigimod After Futility Review in S... Read Post »
Drugs Safety AlertUK Revokes IXCHIQ Marketing Authorization After Benefit-Risk Review UK Revokes IXCHIQ Marketing Authorization After Benefit-Risk Review Read Post »
